Browse > Article
http://dx.doi.org/10.14478/ace.2022.1074

The Developing Trend of Cardiovacular Drug Coated Balloon Catheter  

Park, Junghun (CG Bio Co., Ltd.)
Jo, Won-Il (CG Bio Co., Ltd.)
Byeon, Dae-Heung (CG Bio Co., Ltd.)
Kang, So Young (CG Bio Co., Ltd.)
Nam, Choong-hyun (CG Bio Co., Ltd.)
Seo, Kyoung-Woo (Department of Cardiology, Ajou University School of Medicine)
Park, Jun-Kyu (CG Bio Co., Ltd.)
Publication Information
Applied Chemistry for Engineering / v.33, no.5, 2022 , pp. 545-550 More about this Journal
Abstract
As a result of the rapid entry into an aging society and westernized eating habits, the number of heart disease patients caused by angina pectoris, myocardial infarction, and high blood pressure has increased by more than 100,000 over five years. Heart disease has consistently ranked second in the cause of death in Korea over the past eight years, and medical expenses consumed annually reach 6 trillion won. While various treatments are being proposed for more patients, drug-coated balloon catheters have been developed and gradually commercialized to solve the disadvantages of stent implantation such as restenosis and increased risk of bleeding due to long-term double antiplatelet medication. In Korea, it began to use a drug-coated balloon catheter with the first release of it called "SeQuent PleaseⓇ (Bibrown Korea)" in 2010. Its demand increased gradually as insurance benefits were applied in 2012. Drug-coated balloon angioplasty is increasing in use not only in Korea but also around the world, especially in the Asia-Pacific region, including Japan. Until now, the demand for domestic products is increasing, and if the efficiency in vivo and clinical trials is proven in the future, it is expected to be an effective procedure compared to high-risk stent implantation.
Keywords
Coated balloon; Sirolimus; Paclitaxel; Cardiovascular; Coroanry artery disease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. G. Raja, B, Bendetto, C. D. Ilseley, and M. Amrani, Multiple arterial grafting confers survival advantage compared to percutaneous intervention with drug-eluting stents in multivessel coronary artery disease: A propensity score adjusted analysis, Int. J. Cardiol., 189, 153-158 (2015).   DOI
2 S. Kuramitsu, S. Sonoda, K. Ando, H. Otake, M. Natsuaki, R. Anai, Y. Honda, K. Kadota, Y. Kobayashi, and T. Kimura, Drug-eluting stent thrombosis: Current and future perspectives, Cardiovasc. Interv. Ther., 36, 158-168 (2021).   DOI
3 J. Torrado, L. Buckley, A. Duran, P. Trujillo, S. Toldo, J. V. Raleigh, A. Abbate, G. Biondi-Zoccai, and L. A. Guzman, Restenosis, stent thrombosis, and bleeding complications: Navigating between scylla and charybdis, J. Am. Coll. Cardiol., 71, 1676-1695 (2018).   DOI
4 R. V. Jeger, S. Eccleshall, W. A. W. Ahmad, J. Ge, T. C. Poerner, E. S. Shin, F. Alfonso, A. Latib, P. J. Ong, T. T. Rissanen, J. Saucedo, B. Scheller, and F. X. Kleber, Drug-coated balloons for coronary artery disease: Third report of the International DCB Consensus Group, JACC Cardiovasc. Interv., 13, 1391-1402 (2020).   DOI
5 R. V. Jeger, A. A. Farah, M. A. Ohlow, N. Manger, S. Mobius-Winkler, D. Weilenmann, G. Stachel, S. Markovic, G. Leibundgut, P. Rickenbacher, S. Osswald, M. Cattaneo, N. Gilgen, C. Kaiser, and B. Scheller, Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial, Lancet, 396, 1504-1510 (2020).   DOI
6 R. A. Byrne, M. Joner, F. Alfonso, and A. Kastrati, Drug-coated balloon therapy in coronary and peripheral artery disease, Nat. Rev. Cardiol., 11, 13-23 (2014).   DOI
7 F. X. Kleber, H. Rittger, K. Bonaventura, U. Zeymer, J. Wohrle, R. Jeger, B. Levenson, S. Mobius-Winkler, L. Bruch, D. Fischer, C. Hengstenberg, T. Porner, D. Mathey, and B. Scheller, Drug-coated balloons for treatment of coronary artery disease: Updated recommendations from a consensus group, Clin. Res. Cardiol., 102, 785-797 (2013).   DOI
8 S. Bose. S. S. Keller, T. S. Alstrom, A. Boisen, and K. Almdal, Process optimization of ultrasonic spray coating of polymer films, Langmuir, 29, 6911-6919 (2013).   DOI
9 Transparency Market Research, Drug Eluting Balloon Market (Product - Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon; Drug Coating Technology - Paccocath, FreePac, TransPax, EnduraCoat) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026, New York, USA (2022).
10 I. Rykowska, I. Nowak, and R. Nowak, Drug-eluting stents and balloons-materials, structure designs, and coating techniques: A review, Molecules, 25, 4624 (2020).   DOI
11 J. Ju, Y. Yamagata, and T. Higuchi, Thin-film fabrication method for organic light-emitting diodes using electrospray deposition, Adv. Mater., 21, 4343-4347 (2009).   DOI
12 M. Bukka, P. J. Rednam, and M. Sinha, Drug-eluting ballon: Design, technology and clinical aspects, Biomed. Mater., 13, 032001 (2018).   DOI
13 S. Sharma, N. Kukreja, C. Christopoulos and D. A. Gorog, Drug-eluting balloon: New tool in the box, Expert Rev. Med. Devices, 7, 381-388 (2014).   DOI
14 T. Shazly, W. M. Torees, E. A. Secemsky, C. C. Chitalia, F. A. Jaffer, V. B. Kolachalam, Understudied factors in drug-coated balloon design and evaluation: A biophysical perspective, Bioeng. Transl. Med., Doi: 10.1002/btm2.10370.   DOI